983

SHORT- AND LONG-TERM GUT MUCOSAL ADAPTATIONS TO DIET-INDUCED WEIGHT LOSS COMPARED TO ROUX-EN-Y-INDUCED WEIGHT LOSS IN PATIENTS WITH OBESITY

Date
May 21, 2024

Introduction: Enteroendocrine cells (EEC) secrete satiety hormones Glucagon-like peptide 1 (GLP-1) and Peptide YY (PYY) in response to luminal content through nutrient-sensing GPCRs. In obesity, diet-induced weight loss (WL) by caloric restriction result in adaptations including reductions in postprandial levels of GLP-1 and PYY. Conversely, WL after Roux-en-Y Gastric Bypass (RYGB) is associated with increased postprandial levels of GLP-1 and PYY. We recently identified expression of regulator of G-protein signaling 9 (RGS9), a negative regulator of GPCR signaling, in human EECs and show that it may function to cease GLP-1 and PYY secretion. We hypothesized that RGS9 may play a role in altered synthesis or secretion of GLP-1 and PYY from EECs during WL interventions in humans. In the present study, we aimed to elucidate the role of RGS9 in Diet- and RYGB-induced WL in patients with obesity.
Methods: We recruited participants for two cohorts: 1)RYGB (n=8, age 42±4y, BMI 46±2kg/m2, 80% female) and 2) matched-controls based on age, BMI and gender for a Diet-only intervention that was calorie-matched, WL-matched to the RYGB diet(n=8, age 41±4y, BMI 45±2kg/m2, 75% female)(Table 1). The Diet-only cohort followed the same post-RYGB diet: 500kcal/day wk1, 600kcal/day wk2-4, 600-800kcal/day wk5-8, 800-1000kcal/day wk9-12. Eight participants followed up >1yr with RYGB (n=4) or Diet-only (n=4). At BSL, 9-weeks, and 1yr FU, intestinal mucosal biopsies were collected via endoscopy, and blood plasma was collected at fasting and at 15-min intervals after a meal. GLP-1 and PYY blood levels were assayed using ELISA. Area under the curve from fasting to 90mins (AUC0-90) for BSL, 9-wks and >1yr was calculated. RNAlater preserved biopsies were processed for RT-qPCR gene expression.
Results: There were no significant differences in BSL characteristics, WL, %TBWL, or WL rate (kg/day) at 9-weeks between intervention. At >1yr FU, RYGB group achieved more %TBWL than the diet group compared to BSL (Fig1A)(p<0.01). At 9-weeks, there were no differences in the GLP-1 or PYY AUC0-90(Fig1B-C) between interventions compared to BSL. At >1yr FU, RYGB group had significantly higher GLP-1 (p<0.05) and PYY(p<0.05) AUC0-90 than diet group. Intestinal expression of GCG, PYY and RGS9 were unchanged between interventions at all time points (Fig1D-F). Regardless of intervention, weight loss was associated with increased RGS9 fold-change at 9wks(FigG-H, p=0.054, p=0.05), but this trend was nonsignificant trend at >1yr(p=0.08).
Conclusions: At 1-year post intervention RYGB is associated with increased postprandial GLP-1 and PYY, without respective changes in intestinal gene expression. While at 9-weeks, TBWL is associated with increased RGS9. Suggesting that in the long-term, gut adaptations in plasma hormone levels appear to be occurring independently from gut RGS9 in RYGB.
Table 1. Patient demographics for two interventions: RYGB and matched-controls based on age, BMI and gender for a Diet-only intervention that was calorie-matched, WL-matched to the RYGB group.

Table 1. Patient demographics for two interventions: RYGB and matched-controls based on age, BMI and gender for a Diet-only intervention that was calorie-matched, WL-matched to the RYGB group.

<b>Figure 1.</b> Gut mucosal adaptations to 9-weeks and >1 year weight loss with RYGB or Diet-only A.) Total body weight loss (TBWL%). Area under the curve from fasting to 90 minutes postprandial for B) GLP-1 and C) PYY plasma levels. Intestinal mRNA exressionD) GCG E)PYY F)RGS9. G) Paired intestinal RGS9 mRNA expression at BSL and after 9wks between groups, and H)TBWL(%) correlation with fold change of <i>RGS9 </i>from BSL to 9wks. *p<0.05, **p<0.01.

Figure 1. Gut mucosal adaptations to 9-weeks and >1 year weight loss with RYGB or Diet-only A.) Total body weight loss (TBWL%). Area under the curve from fasting to 90 minutes postprandial for B) GLP-1 and C) PYY plasma levels. Intestinal mRNA exressionD) GCG E)PYY F)RGS9. G) Paired intestinal RGS9 mRNA expression at BSL and after 9wks between groups, and H)TBWL(%) correlation with fold change of RGS9 from BSL to 9wks. *p<0.05, **p<0.01.


Tracks

Related Products

Thumbnail for REGULATOR OF G-PROTEIN SIGNALING AS AN ENTEROENDOCRINE-SPECIFIC TARGET FOR OBESITY TREATMENT: ALTERED RGS9 IN ENTEROENDOCRINE CELLS IMPAIRS POSTPRANDIAL GLP-1 RESPONSE AND MODIFIES FOOD INTAKE IN MICE
REGULATOR OF G-PROTEIN SIGNALING AS AN ENTEROENDOCRINE-SPECIFIC TARGET FOR OBESITY TREATMENT: ALTERED RGS9 IN ENTEROENDOCRINE CELLS IMPAIRS POSTPRANDIAL GLP-1 RESPONSE AND MODIFIES FOOD INTAKE IN MICE
Enteroendocrine cells play a major role in sensing the luminal contents of the gut and communicating with other organs such as the pancreas, liver and brain. The gut-brain connection is essential in the regulation of food intake…
Thumbnail for PERFORMANCE OF A MACHINE-LEARNING GENE RISK SCORE BIOMARKER ON PREDICTING RESPONSE TO SEMAGLUTIDE: A PROSPECTIVELY FOLLOWED MULTI-CENTER BIOBANK AND OUTCOMES REGISTRY
PERFORMANCE OF A MACHINE-LEARNING GENE RISK SCORE BIOMARKER ON PREDICTING RESPONSE TO SEMAGLUTIDE: A PROSPECTIVELY FOLLOWED MULTI-CENTER BIOBANK AND OUTCOMES REGISTRY
BACKGROUND: Our phenotype-guided approach to antiobesity medications is associated with greater weight loss compared to the obesity medicine standard of care…
Thumbnail for WEIGHT LOSS OUTCOMES WITH SEMAGLUTIDE BASED ON DIABETES STATUS AND SEVERITY USING THE INDIVIDUALIZED METABOLIC SURGERY SCORE
WEIGHT LOSS OUTCOMES WITH SEMAGLUTIDE BASED ON DIABETES STATUS AND SEVERITY USING THE INDIVIDUALIZED METABOLIC SURGERY SCORE
Background: Transoral outlet reduction endoscopy (TORe) has been shown to be effective in managing weight regain after Roux-en-Y gastric bypass (RYGB), as has the glucagon-like peptide-1 agonist, liraglutide. However, the effect of adjunctive liraglutide after TORe has yet to be assessed…